Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) will report first-quarter 2026 corporate and financial results on Wednesday, May 6, 2026 via a news release after the market close and host a conference call/audio webcast at 4:30 p.m. ET.
A link and replay (available for 90 days beginning ~5:30 p.m. ET) will be on the Events & Presentations page at investors.zevra.com. Telephone dial-in and Conference ID ZVRAQ126 are provided for participants.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the Apr 22 session, ZVRA gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Q4/FY25 earnings | Positive | +21.3% | Strong Q4 and FY2025 revenue and profitability with MIPLYFFA driving growth. |
| Mar 02 | Q4 call details | Neutral | +1.8% | Announcement of timing and access details for Q4 and FY2025 earnings call. |
| Nov 05 | Q3 2025 earnings | Positive | -9.7% | Q3 revenue ramp and sharply reduced net loss with strong cash position. |
| Oct 27 | Q3 call details | Neutral | +4.4% | Scheduled Q3 2025 results release and call logistics for investors. |
| Aug 12 | Q2 2025 earnings | Positive | -19.8% | Strong Q2 revenue, PRV sale proceeds, and solid cash while posting net income. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings result releases have sometimes seen sharp moves in both directions, while call‑detail announcements tend to have more moderate reactions.
Recent earnings-related news for Zevra shows a mix of strong fundamentals and varied price reactions. Q2 and Q3 2025 results featured growing MIPLYFFA-driven revenue and improving losses, yet shares moved -19.81% and -9.73% afterward. By Q4 and full-year 2025, net revenue reached $106.5M with net income of $83.2M, and the stock rose 21.27%. Prior call-detail notices, such as those on Aug 12, 2025 and Oct 27, 2025, produced smaller, mixed moves, framing today’s Q1 2026 call notice as part of a regular cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter on Wednesday, May 6, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
To join via telephone, please use the following dial-in information:
- (800) 579-2543 (United States)
- +1 (785) 424-1789 (International)
- Conference ID: ZVRAQ126
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
